MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

Inicio・Lista de Acciones・Fate Therapeutics Inc

Fate Therapeutics Inc

Cerrado

SectorSanidad

0.97 -2.02

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.96

Máximo

0.99

Métricas clave
By Trading Economics
Ingresos	1.8M -32M
Ventas	-166K 1.7M
Margen de beneficios	-1,852.384
Empleados	181
EBITDA	7.9M -29M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+400% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-11M 115M
Apertura anterior	2.99
Cierre anterior	0.97

Noticias sobre sentimiento de mercado

By Acuity

50%

310 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

0.9101 / 1.14 Soporte y Resistencia

Fate Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 dic 2025, 23:49 UTC

Adquisiciones, fusiones, absorciones

WiseTech to Sell Expedient to Appease Competition Regulator

30 dic 2025, 17:12 UTC

Principales Movimientos del Mercado

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

30 dic 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30 dic 2025, 21:08 UTC

Charlas de Mercado

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30 dic 2025, 20:41 UTC

Charlas de Mercado

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30 dic 2025, 20:37 UTC

Ganancias

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30 dic 2025, 19:29 UTC

Charlas de Mercado

Corn Extends Pullback in Light Trade -- Market Talk

30 dic 2025, 18:29 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

30 dic 2025, 16:20 UTC

Ganancias

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30 dic 2025, 16:18 UTC

Adquisiciones, fusiones, absorciones

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30 dic 2025, 16:10 UTC

Charlas de Mercado

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30 dic 2025, 15:24 UTC

Charlas de Mercado

Australian Dollar Could Rise Versus Sterling -- Market Talk

30 dic 2025, 15:10 UTC

Adquisiciones, fusiones, absorciones

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30 dic 2025, 14:24 UTC

Adquisiciones, fusiones, absorciones

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30 dic 2025, 14:22 UTC

Adquisiciones, fusiones, absorciones

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30 dic 2025, 14:20 UTC

Adquisiciones, fusiones, absorciones

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30 dic 2025, 14:17 UTC

Adquisiciones, fusiones, absorciones

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30 dic 2025, 14:16 UTC

Adquisiciones, fusiones, absorciones

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30 dic 2025, 14:14 UTC

Adquisiciones, fusiones, absorciones

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30 dic 2025, 14:12 UTC

Adquisiciones, fusiones, absorciones

LVMH: Les Editions Croque Futur Is a French Publishing House

30 dic 2025, 14:10 UTC

Adquisiciones, fusiones, absorciones

LVMH Acquires Les Editions Croque Futur

30 dic 2025, 13:49 UTC

Adquisiciones, fusiones, absorciones

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30 dic 2025, 13:36 UTC

Charlas de Mercado

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30 dic 2025, 13:30 UTC

Charlas de Mercado

Crude Futures Gain in Light Holiday Trade -- Market Talk

30 dic 2025, 12:55 UTC

Charlas de Mercado

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30 dic 2025, 11:55 UTC

Charlas de Mercado

Ganancias

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30 dic 2025, 11:47 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30 dic 2025, 11:35 UTC

Adquisiciones, fusiones, absorciones

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Comparación entre iguales

Cambio de precio

Fate Therapeutics Inc previsión

Precio Objetivo

By TipRanks

400% repunte

Estimación a 12 Meses

Media 5 USD 400%

Máximo 8 USD

Mínimo 2 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Fate Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Fate Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.9101 / 1.14Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentimiento

By Acuity

310 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.